Evaluating Telitacicept with Standard Therapy for Difficult-to-Treat Rheumatoid Arthritis in a Randomized Controlled Trial
Led by Peking University People's Hospital · Updated on 2026-09-01
420
Participants Needed
47
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating telitacicept for adults with difficult-to-treat rheumatoid arthritis, a form of the disease not well controlled by standard treatments. This multicenter, open-label randomized trial aims to assess the safety and effectiveness of telitacicept over a 24-week treatment period, followed by a 2-week follow-up. The study involves patients whose disease remains active despite multiple disease-modifying therapies.
Participants are randomly assigned to one of two groups one group receives weekly subcutaneous injections of 160 mg telitacicept along with standard therapy, while the other group continues with standard therapy alone. Standard therapy includes disease-modifying antirheumatic drugs, glucocorticoids, and non-steroidal anti-inflammatory drugs. The treatment period lasts for 24 weeks.
During the study, participants will be regularly monitored through clinical assessments and laboratory tests to evaluate their response using measures like the ACR20 response rate at week 24. Researchers will also assess other disease activity indices and safety parameters. After the treatment period, participants have a 2-week follow-up to assess ongoing effects and safety. Total participation lasts about 26 weeks.
CONDITIONS
Brief Title
Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis
Research Team
Z
zhanguo LI, PHD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 24 weeks
Participants receive either weekly subcutaneous injections of telitacicept plus standard therapy or standard therapy alone for 24 weeks.
Weekly visits
Follow-up
Duration - 2 weeks
Participants are monitored for 2 weeks after treatment to assess safety and ongoing effects.
1 visit
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Study of Vitamin E Supplementation to Reduce Inflammation and Symptoms in Women with Rheumatoid Arthritis
Using Advanced 7 Tesla MRI Brain Imaging to Understand How Filgotinib Relieves Pain in Adults with Rheumatoid Arthritis
Evaluating Safety and Dose Levels of MK-1045 in Adults with Lupus or Rheumatoid Arthritis
Phase 1 Study Evaluating Safety and Drug Behavior of CND319 in Healthy Adults and Patients with Rheumatic Diseases
Study of NKX019, a CAR NK Cell Therapy Targeting CD19, in Adults With Autoimmune Diseases
Phase 1b Open-label Trial to Assess Safety and Effects of Plamotamab Injection in Adults With Moderate to Severe Rheumatoid Arthritis
Phase 1b2 Study of AZD0120 Dual Targeting CAR T-cell Therapy in Adults with Autoimmune Diseases Including Systemic Sclerosis and Rheumatoid Arthritis
Phase I Study Evaluating Safety, Effectiveness, and Dosing of GNC-038 Antibody Injection for Rheumatoid Arthritis Treatment
Evaluation of Safety and Tolerability of Intravenous CPTX2309 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis or Systemic Lupus Erythematosus
Phase 1 Study of LY4298445 Safety and Tolerability in Healthy Adults and Adults With Systemic Lupus Erythematosus or Rheumatoid Arthritis
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.